| Latest Valirx News Headlines |
| Date | Time | Source | |
| 09/16/2008 | 3:07AM | TFNF | ValiRx develops prototype non-invasive test for cancer
ValiRx Plc. said it has developed a prototype
'Nucleosomics' non-invasive test for cancer detection and its diagnostics
division in Belgium is now progressing to the next stage of development, which
will include testing patient blood samples.
ValiBio now plans to use this first prototype test to determine... More...>> |
| 09/16/2008 | 2:00AM | UKREG | Update on cancer detection test
RNS Number : 4927D
ValiRx PLC
16 September 2008
ValiRx plc
ValiRx develops prototype non-invasive test for cancer
16 September 2008, London. ValiRx (AIM: VAL, "ValiRx", "the Company"), the cancer therapeutics and diagnostics company, has announced
that its diagnostics division in Belgium... More...>> |
| 09/11/2008 | 2:57AM | TFNF | ValiRx H1 pretax loss widens; on track to launch first diagnostic product soon
ValiRx Plc., the cancer therapeutics and
diagnostics company, reported a wider first half pretax and operating loss but
said the company is on track to launch its first diagnostic products over the
next six months.
For the first half to end-June, ValiRx reported a pretax loss of 528,341
pounds from a loss... More...>> |
| 09/11/2008 | 2:00AM | UKREG | Interim Results
RNS Number : 1817D
ValiRx PLC
11 September 2008
ValiRx plc
Interim results
11 September 2008, London. ValiRx plc (AIM: VAL, "ValiRx", "the Company") the cancer therapeutics and diagnostics company, announces its
interim results for the six months ended 30 June 2008.
Highlights... More...>> |
| 09/10/2008 | 5:33AM | UKREG | Notice of Results
RNS Number : 1192D
ValiRx PLC
10 September 2008
10 September 2008
ValiRx plc
Notice of Interim Results - Thursday 11 September 2008
ValiRx plc (AIM:VAL), the cancer therapeutics company, will be announcing its Interim Results for the six months ended 30 June 2008 on
Thursday... More...>> |
| 08/18/2008 | 11:02AM | UKREG | Appointment of director
RNS Number : 5624B
ValiRx PLC
18 August 2008
18 August 2008
ValiRx plc
("ValiRx" or the "Company")
Appointment of director
ValiRx (AIM:VAL), the cancer therapeutics and diagnostics company, has appointed Dr Norman Hardman as a non-executive director. Dr
Hardman will join... More...>> |
| 07/31/2008 | 2:01AM | UKREG | Total Voting Rights
RNS Number : 2661A
ValiRx PLC
31 July 2008
31 July 2008
ValiRx plc
Total Voting Rights
For the purposes of the transitional provisions of the Financial Services Authority's Disclosure and Transparency Rules, the total number of
ordinary shares of 6p each in the capital of... More...>> |
| 07/28/2008 | 9:48AM | UKREG | AGM Statement
RNS Number : 0305A
ValiRx PLC
28 July 2008
28 July 2008
ValiRx PLC
Result of AGM
At the Annual General Meeting of ValiRx plc (AIM:VAL, 'ValiRx') the cancer therapeutics and diagnostics company, held earlier today, all
the resolutions put to shareholders were duly... More...>> |
| 07/23/2008 | 11:02AM | UKREG | Director's Dealing
RNS Number : 7377Z
ValiRx PLC
23 July 2008
ValiRx plc
Director's dealing
23 July 2008, London. ValiRx plc (AIM:VAL, 'ValiRx') the cancer therapeutics and diagnostics company, announces that on 21 July 2008
Kevin Alexander received 266,666 existing warrants over ordinary shares of... More...>> |
| 07/14/2008 | 9:23AM | UKREG | Director/PDMR Shareholding
RNS Number : 0110Z
ValiRx PLC
14 July 2008
ValiRx plc
Directors' shareholdings
14 July 2008, London. ValiRx plc (AIM:VAL, 'ValiRx') the cancer therapeutics and diagnostics company, announces Dr Satu Vainikka and
Gerry Desler, both directors of the Company, have today purchased the following... More...>> |
| 07/14/2008 | 2:34AM | TFNF | ValiRx acquires Cronos Therapeutics in 374,000 pound deal
ValiRx Plc., the cancer therapeutics and
diagnostics company, said it has exercised an option to acquire the final 39.7
percent of Cronos Therapeutics in a 374,000 pound deal.
ValiRx said it has also issued 6.5 million new shares in the combined
company at 6 pence each to Cronos minority shareholders... More...>> |
| 07/14/2008 | 2:00AM | UKREG | ValiRx acquires Cronos Therapeutics
RNS Number : 9478Y
ValiRx PLC
14 July 2008
ValiRx plc
Acquisition of shares in Cronos Therapeutics and directors' shareholding
14 July 2008, London. ValiRx plc (AIM:VAL, 'ValiRx') the cancer therapeutics and diagnostics company, announces that, pursuant to the
call option agreement... More...>> |
| 07/09/2008 | 2:00AM | UKREG | ValiRx Acquires Global Rights to Novel Compound
RNS Number : 6291Y
ValiRx PLC
09 July 2008
9 July 2008
ValiRx plc
ValiRx Acquires Global Rights to Novel Compound
Targeted at Prostate Cancer
9 July 2008, London *.. ValiRx plc (AIM:VAL, 'ValiRx'), the cancer therapeutics and diagnostics company, has entered into a Licence
Agreement... More...>> |
| 06/30/2008 | 11:38AM | UKREG | Joint Broker Appointment
RNS Number : 9262X
ValiRx PLC
30 June 2008
30 June 2008
ValiRx plc
Appointment of Joint Broker
ValiRx plc (AIM:VAL, 'the Company'), the cancer therapeutics and diagnostics company, has appointed Old Park Lane Capital plc as the
Company's Joint Broker to work with the Company's... More...>> |
| 06/30/2008 | 2:28AM | TFNF | ValiRx FY pretax loss 1.3 mln pounds vs 316,069 pounds, sees sales in early 2009
ValiRx Plc, the AIM-listed cancer
biopharmaceutical company, has reported a full-year pretax loss of 1.3 million
pounds compared with 316,069 pounds last year and in line with the company's
expectations.
In a statement, ValiRx chief executive Satu Vainikkasaid predicted that the
company would book its first... More...>> |
| 06/30/2008 | 2:01AM | UKREG | Final Results
RNS Number : 7930X
ValiRx PLC
30 June 2008
VALIRX PLC
("ValiRx" or the "Company")
AUDITED RESULTS FOR THE 12 MONTH PERIOD ENDED 31 DECEMBER 2007
30 June 2008, London * ValiRx (AIM: VAL), the cancer therapeutics and diagnostics company, today announces its final results for the
twelve... More...>> |
| 06/26/2008 | 4:22AM | TFNF | UK smallcap opening - Publishing Technology gains on update, contract win
Publishing Technology notched up a 13 percent
gain -- or 0.075 of a penny to 0.65 of a penny -- after the technology and
marketing services company said its revenue has increased quarter on quarter and
its overheads have fallen. It added that it sees recurring revenue exceeding 65
percent of total revenue for... More...>> |
| 06/26/2008 | 3:53AM | TFNF | ValiRx reports promising results for lead molecule to target pancreatic cancer
ValiRx Plc. said the in vivo results for its
lead molecule VAL 101, which uses its gene silencing technology GeneICE in
pre-clinical xenograph models of pancreatic cancer, are "promising".
The cancer therapeutics and diagnostics company said studies showed that the
tumour growth was less than half the size... More...>> |
| 06/26/2008 | 2:01AM | UKREG | Therapeutic Pipeline - in vivo results
RNS Number : 5538X
ValiRx PLC
26 June 2008
26 June 2008
ValiRx plc
Promising In Vivo Data for VAL 101 Compound - targets Pancreatic Cancer, based on GeneICE* Gene Silencing Technology
26 June 2008, London *.. ValiRx plc (AIM:VAL, 'ValiRx'), the cancer therapeutics and diagnostics... More...>> |
| 06/23/2008 | 3:00AM | UKREG | Notice of Results
RNS Number : 2423X
ValiRx PLC
23 June 2008
23 June 2008
ValiRx plc
Notice of Preliminary Results
ValiRx plc (AIM:VAT), the cancer therapeutics company, will be announcing its Preliminary Results for the year ended 31 December 2007 on
Monday 30 June 2008.
Enquiries:... More...>> |